FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number:    

 
 
CIBMTR Recipient ID:    

 
 

Has this patient's data been previously reported to USIDNET?

  
 nmlkji

yes  
 nmlkji

no  

 
 
USIDNET ID:    

 
 
Today's Date: __ __ __ __ - __ __- __ __  

 
 
Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HSCT type: (check all that apply) 

 
  

gfedcb
Autologous

 
 

  
gfedcb

Allogeneic, unrelated

 
 

  
gfedcb

Allogeneic, related

 
 

  
gfedcb

Syngeneic (identical twin)

 

Product type: (check all that apply) 

 
  

gfedcb
Marrow

 
 

  
gfedcb

PBSC

 
 

  
gfedcb

Cord blood

 
 

  
gfedcb

Other product

 
 
specify    

 
 

  
gfedcb

If this is a report of a second or subsequent transplant, check here.

  Continue with question 116.   

 

Disease assessment at diagnosis includes disease characteristics observed within six weeks of the date of diagnosis. 
 
1  What was the date of diagnosis of Immune Deficiency (ID)? __ __ __ __ - __ __- __ __  

 
 
2  What is the immune deficiency molecular abnormality?   

 
 
3  Specify molecular abnormality:    

 
 
4  Specify other abnormality:    

 
 

5  Is the mutated protein or enzyme expressed?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

6  What is the pattern of inheritance for the genetic disorder?

    
 nmlkji

sporadic (no family history)  

 nmlkji
x-linked, documented  

 nmlkji
autosomal recessive, documented  

 nmlkji
Unknown  

 
 

7  Are the parents of the patient consanguineous (related by blood ancestry)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

8  Are there other blood relatives in the patient's family with immunodeficiency disease?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  Key Fields 

Disease Assessment at Diagnosis Questions: 1 - 8

Form 2031 R3.0: Immune Deficiencies Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2031 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 12



 

Report findings prior to any first treatment of the primary disease for which the HSCT is being performed. 
 
9  Date CBC tested: (testing done within 6 weeks of diagnosis) __ __ __ __ - __ __- __ __  

 
 
10    

gfedcb
WBC not tested

  
 
WBC:    

 
.

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

  
 
11    

gfedcb
Lymphocytes not tested

 
Lymphocytes:    % 

  
 
12    

gfedcb
Eosinophils not tested

 
Eosinophils:    % 

  
 
13    

gfedcb
Polymorphonuclear leukocytes (PMN) not tested

 
Polymorphonuclear leukocytes (PMN):    % 

 
 
14    

gfedcb
Hemoglobin not tested

  
 
Hemoglobin:    

 
.

 nmlkji
g/dL  

 nmlkji
g/L  

 nmlkji
mmol/L  

 
 

  
gfedcb

transfused RBC < 30 days from date of test

 
 
15    

gfedcb
Platelets not tested

  
 
Platelets:    

 
.

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 

  
gfedcb

transfused platelets < 7 days from date of test

 
 
16    

gfedcb
IgG not tested

  
 
IgG:    

 
.

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 
17  Date tested: __ __ __ __ - __ __- __ __  

 
 
18    

gfedcb
IgM not tested

  
 
IgM:    

 
.

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 
19  Date tested: __ __ __ __ - __ __- __ __  

 
 
20    

gfedcb
IgA not tested

  
 
IgA:    

 
.

 nmlkji
mg/dL  

 nmlkji
g/dL  

 nmlkji
g/L  

 
 
21  Date tested: __ __ __ __ - __ __- __ __  

  
 
22    

gfedcb
IgE not tested

 
IgE:    IU/mL 

 
 
23  Date tested: __ __ __ __ - __ __- __ __  

 
 

24  Did the recipient receive supplemental intravenous immunoglobulins (IVIG) prior to any first treatment of ID?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

25  Was therapy ongoing within one month of immunoglobulin testing?

    
 nmlkji

yes  
 nmlkji

no  

 

Lymphocyte Analysis 

Specify the following lymphocyte analyses performed prior to any disease treatment: 

 
26  Were lymphocyte analyses performed?

    
 nmlkji

yes  
 nmlkji

no  

 
 
27  Date of most recent testing performed: __ __ __ __ - __ __- __ __  

  Laboratory Studies at Diagnosis Questions: 9 - 50

Form 2031 R3.0: Immune Deficiencies Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2031 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 12



 
 
28  Absolute lymphocyte count:    cells / uL (cells / (mm)**3) 

 
 
29    

gfedcb
CD3 (T cells) not tested

 
 
CD3 (T cells) % of total lymphocytes    % 

  

-- or -- 
 
CD3 (T cells) value    

 
.

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 
30    

gfedcb
CD4 (T helper cells) not tested

 
 
CD4 (T helper cells) % of total lymphocytes    % 

  

-- or -- 
 
CD4 (T helper cells) value    

 
.

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 
31    

gfedcb
CD8 (cytotoxic T cells) not tested

 
 
CD8 (cytotoxic T cells) % of total lymphocytes    % 

  

-- or -- 
 
CD8 (cytotoxic T cells) value    

 
.

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 
32    

gfedcb
CD20 (B lymphocyte cells) not tested

 
 
CD20 (B lymphocyte cells) % of total lymphocytes    % 

  

-- or -- 
 
CD20 (B lymphocyte cells) value    

 
.

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 
33    

gfedcb
CD56 (natural killer (NK) cells) not tested

 
 
CD56 (natural killer (NK) cells) % of total lymphocytes    % 

  

-- or -- 
 
CD56 (natural killer (NK) cells) value    

 
.

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 
34    

gfedcb
CD4+/CD45RA+ (memory T cells) not tested

 
 
CD4+/CD45RA+ (naive T cells) % of total lymphocytes    % 

  

-- or -- 
 
CD4+/CD45RA+ (naive T cells) value    

 
.

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

 
 
35    

gfedcb
CD4+/CD45RO+ (memory T cells) not tested

 
 
CD4+/CD45RO+ (memory T cells) % of total lymphocytes    % 

  

-- or -- 
 
CD4+/CD45RO+ (memory T cells) value    

 
.

 nmlkji
x 109/L (x 103/mm3)  

 nmlkji
x 106/L  

Form 2031 R3.0: Immune Deficiencies Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2031 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 12



 

Antibody Response 
 
36  Date antibody responses were assessed: (date closest to diagnosis, before any IVIG) __ __ __ __ - __ __- __ __  

 
 

37  Bacteriophage phi X-174 or other neoantigen

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

 
 

38  Diptheria

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

 
 

39  Isohemagglutinin anti-A

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

 
 

40  Isohemagglutinin anti-B

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

 
 

41  Protein conjugated HIB or pneumococcal vaccine

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

 
 

42  Tetanus

    
 nmlkji

Absent  
 nmlkji

Low  
 nmlkji

Normal  
 nmlkji

Not Tested  

  
 
43  Unconjugated pneumococcal polysaccharide:     /  

 
.    

  Number of serotypes producing a protective level / Total serotypes tested from vaccine  

 

Lymphocyte Function 
 
44  Date lymphocyte function was assessed: __ __ __ __ - __ __- __ __  

 
 

45  Anti-CD3

    
 nmlkji

Absent (<10% of control)  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal (>30% of control)  

 nmlkji
Not Tested  

 
 

46  Candida antigen

    
 nmlkji

Absent (<10% of control)  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal (>30% of control)  

 nmlkji
Not Tested  

 
 

47  Concavalin A (ConA)

    
 nmlkji

Absent (<10% of control)  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal (>30% of control)  

 nmlkji
Not Tested  

 
 

48  Phytohemagglutinin (PHA)

    
 nmlkji

Absent (<10% of control)  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal (>30% of control)  

 nmlkji
Not Tested  

Form 2031 R3.0: Immune Deficiencies Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2031 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 12



 
 

49  Pokeweed mitogen (PWM)

    
 nmlkji

Absent (<10% of control)  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal (>30% of control)  

 nmlkji
Not Tested  

 
 

50  Tetanus antigen

    
 nmlkji

Absent (<10% of control)  

 nmlkji
Low (10-30% of control)  

 nmlkji
Normal (>30% of control)  

 nmlkji
Not Tested  

 
 

51  Site of infection: hepatitis

    
 nmlkji

yes  
 nmlkji

no  

 
 
52  Organism:   

 
 
53  Specify:    

 
 

54  If hepatitis was present, was it a prominent feature of ID?

    
 nmlkji

yes  
 nmlkji

no  

 
 

55  Site of infection: meningitis/encephalitis

    
 nmlkji

yes  
 nmlkji

no  

 
 
56  Organism:   

 
 
57  Specify:    

 
 

58  If meningitis / encephalitis was present, was it a prominent feature of ID?

    
 nmlkji

yes  
 nmlkji

no  

 
 

59  Site of infection: pneumonia

    
 nmlkji

yes  
 nmlkji

no  

 
 
60  Organism:   

 
 
61  Specify:    

 
 

62  If pneumonia was present. was it a prominent feature of ID?

    
 nmlkji

yes  
 nmlkji

no  

 
 

63  Site of infection: severe or protracted diarrhea

    
 nmlkji

yes  
 nmlkji

no  

 
 
64  Organism:   

Clinical Features Assessed between Diagnosis and the Start of the Preparative Regimen Questions: 51 - 115

  Hepatitis Organism (1) Questions: 52 - 53 

  Meningitis / Encephalitis Organism (1) Questions: 56 - 57 

  Pneumonia Organism (1) Questions: 60 - 61 

  Diarrhea Organism (1) Questions: 64 - 65 

Form 2031 R3.0: Immune Deficiencies Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2031 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 12



 
 
65  Specify:    

 
 

66  If diarrhea was present, was it a prominent feature of ID?

    
 nmlkji

yes  
 nmlkji

no  

 
 

67  Site of infection: systemic infection

    
 nmlkji

yes  
 nmlkji

no  

 
 
68  Organism:   

 
 
69  Specify other organism :    

 
 

70  If systemic infection was present, was it a prominent feature of ID?

    
 nmlkji

yes  
 nmlkji

no  

 
 

71  Site of infection: other infection

    
 nmlkji

yes  
 nmlkji

no  

 
 
72  Organism:   

 
 
73  Specify:    

 
 
74  Specify other infection site:    

 
 

75  If other infection was present, was it a prominent feature of ID?

    
 nmlkji

yes  
 nmlkji

no  

 

Clinical Status between Diagnosis and the Preparative Regimen 
 

76  Did the recipient experience any of the following clinical features (between diagnosis and prior to the preparative regimen)?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify clinical features: 
 

77  Is autoimmune hemolytic anemia present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

78  Is autoimmune hemolytic anemia prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

79  Are bone abnormalities present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

80  Are bone abnomalities prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

81  Is edema present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

82  Is edema prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

83  Is eosinophilia present?

    
 nmlkji

yes  
 nmlkji

no  

  Systemic Infection Organism (1) Questions: 68 - 69 

  Other Infection Organism (1) Questions: 72 - 74 

Form 2031 R3.0: Immune Deficiencies Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2031 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 12



 
 

84  Is eosinophilia prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

85  Is failure to thrive (weight<5th percentile) present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

86  Is failure to thrive (weight < 5th percentile) prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

87  Is graft versus host disease due to blood transfusion present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

88  Is graft versus host disease due to blood transfusion prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

89  Is graft versus host disease due to maternal engraftment present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

90  Is graft versus host disease due to maternal engraftment prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

91  Is growth hormone deficiency present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

92  Is growth hormone deficiency prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

93  Is growth retardation (height<5th percentile) present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

94  Is growth retardation (height < 5th percentile) prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

95  Is hepatosplenomogemaly present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

96  Is hepatosplenomegaly prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

97  Is hypoproteinemia present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

98  Is hypoproteinemia prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

99  Is lymphoproliferative disease present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

100  Is lymphoproliferative disease prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

101  Is maternal T-cell engraftment present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

102  Is maternal T-cell engraftment prominent?

    
 nmlkji

yes  
 nmlkji

no  

Form 2031 R3.0: Immune Deficiencies Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2031 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 7 / 12



 
 

103  Is microcephaly present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

104  Is microcephaly prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

105  Is neutropenia present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

106  Is neutropenia prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

107  Is skin rash present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

108  Is skin rash prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

109  Is thrombocytopenia (< 100 x 109/L) present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

110  Is thrombocytopenia (< 100 x 109/L) prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

111  Are warts present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

112  Are warts prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 

113  Are other clinical features present?

    
 nmlkji

yes  
 nmlkji

no  

 
 

114  Are other clinical features prominent?

    
 nmlkji

yes  
 nmlkji

no  

 
 
115  Specify other clinical features:    

 
 

116  Was treatment given (between diagnosis and prior to the preparative regimen)?

    
 nmlkji

yes  
 nmlkji

no  

 

Prophylactic drugs paused for < 1 week should not be considered as "Prophylactic Drug Stopped." 
 

117  Were antifungal drug(s) given as prophylaxis?

    
 nmlkji

yes  
 nmlkji

no  

 
 

118  Were prophlactic antifungal drug(s) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
119    

gfedcb
Date prophylactic antifungal drug(s) stopped unknown

 
 

  
gfedcb

date estimated

 
 
Date prophylactic antifungal drug(s) stopped: __ __ __ __ - __ __- __ __  

 
 

120  Were antiviral drug(s) given as prophylaxis?

    
 nmlkji

yes  
 nmlkji

no  

  Pre-HSCT Treatment for Immune Deficiency Questions: 116 - 191

Form 2031 R3.0: Immune Deficiencies Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2031 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 8 / 12



 
 

121  Were prophylactic antiviral drug(s) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
122    

gfedcb
Date prophylactic antivial drug(s) stopped unknown

 
 

  
gfedcb

date estimated

 
 
Date prophylactic antivial drug(s) stopped: __ __ __ __ - __ __- __ __  

 
 

123  Was co-trimoxazole (Bactim, Septra) given as prophylaxis?

    
 nmlkji

yes  
 nmlkji

no  

 
 

124  Was co-trimoxazole (Bactrim, Septra) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
125    

gfedcb
Date co-trimoxazole (Bactrim, Septr) stopped unknown

 
 

  
gfedcb

date estimated

 
 
Date co-trimoxazole (Bactrim, Septra) stopped: __ __ __ __ - __ __- __ __  

 

Therapy paused for < 1 week should not be considered as “Therapy Stopped.” 
 

126  Was antithymocyte globulin (ATG, ATGAM, Thymoglobulin) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

127  Was antithymocyte globulin (ATG, ATGAM, Thymoglobulin) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
128    

gfedcb
Date antithymocyte globulin (ATG, ATGAM, Thymoglobulin) stopped unknown

 
 

  
gfedcb

date estimated

 
 
Date antithymocyte globulin (ATG, ATGAM, Thymoglobulin) stopped: __ __ __ __ - __ __- __ __  

 
 

129  Were systemic corticosteroids given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

130  Were systemic corticosteroids stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
131    

gfedcb
Date therapeutic systemic corticosteroids stopped unknown

 
 

  
gfedcb

date estimated

 
 
Date systemic corticosteroids stopped: __ __ __ __ - __ __- __ __  

 
 

132  Were topical corticosteroids given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

133  Were therapeutic topical corticosteroids stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
134    

gfedcb
Date therapeutic topical corticosteroids stopped unknown

 
 

  
gfedcb

date estimated

 
 
Date therapeutic topical corticosteroids stopped: __ __ __ __ - __ __- __ __  

 
 

135  Was cyclophosphamide (CTX, Cytoxan, Neosar) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

136  Was therapeutic cyclophosphamide (CTX, Cytoxan, Neosar) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
137    

gfedcb
Date therapeutic cyclophosphamide (CTX, Cytoxan, Neosar) stopped unknown

 
 

  
gfedcb

date estimated

Form 2031 R3.0: Immune Deficiencies Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2031 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 9 / 12



 
 
Date therapeutic cyclophosphamide (CTX, Cytoxan, Neosar) stopped: __ __ __ __ - __ __- __ __  

 
 

138  Was cyclosporine (CsA, Neoral, Sandimmune) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

139  Was therapeutic cyclosporine (CsA, Neoral, Sandimmune) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
140    

gfedcb
Date therapeutic cyclosporine (CsA, Neoral, Sandimmune) stopped unknown

 
 

  
gfedcb

date estimated

 
 
Date therapeutic cyclosporine (CsA, Neoral, Sandimmune) stopped? __ __ __ __ - __ __- __ __  

 
 

141  Was in vivo monoclonal antibody given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify monoclonal antibody: 
 

142  Was alemtuzumab (Campath) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

143  Was therapeutic alemtuzumab (Campath) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
144    

gfedcb
Date therapeutic alemtuzumab (Campath) stopped unknown

 
 

  
gfedcb

date estimated

 
 
Date therapeutic alemtuzumab (Campath) stopped: __ __ __ __ - __ __- __ __  

 
 

145  Was daclizumab (anti-CD25, Zenapax) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

146  Was therapeutic daclizumab (anti-CD25, Zenapax) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
147    

gfedcb
Date therapeutic daclizumab (anti-CD25, Zenapax) stopped unknown

 
 

  
gfedcb

date estimated

 
 
Date therapeutic daclizumab (anti-CD25, Zenapax) stopped: __ __ __ __ - __ __- __ __  

 
 

148  Was etanercept (Enbrel) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

149  Was therapeutic etanercept (Enbrel) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
150    

gfedcb
Date therapeutic etanercept (Enbrel) stopped unknown

 
 

  
gfedcb

date estimated

 
 
Date therapeutic etanercept (Enbrel) stopped: __ __ __ __ - __ __- __ __  

 
 

151  Was infliximab (anti-TNF-α, Remicade) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

152  Was therapeutic infliximab (anti-TNF-α, Remicade) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
153    

gfedcb
Date therapeutic infliximab (anti-TNF-α, Remicade) stopped unknown

 
 

  
gfedcb

date estimated

 
 
Date therapeutic infliximab (anti-TNF-α, Remicade) stopped: __ __ __ __ - __ __- __ __  

Form 2031 R3.0: Immune Deficiencies Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2031 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 10 / 12



 
 

154  Was rituximab (anti-CD20, Rituxan, MabThera) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

155  Was therapeutic rituximab (anti-CD20, Rituxan, MabThera) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
156    

gfedcb
Date therapeutic rituximab (anti-CD20, Rituxan, MabThera) stopped unknown

 
 

  
gfedcb

date estimated

 
 
Date therapeutic rituximab (anti-CD20, Rituxan, MabThera) stopped __ __ __ __ - __ __- __ __  

 
 

157  Was any other monoclonal antibody given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

158  Was therapeutic other monoclonal antibody stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
159    

gfedcb
Date therapeutic other monoclonal antibody stopped unknown

 
 

  
gfedcb

date estimated

 
 
Date therapeutic other monoclonal antibody stopped: __ __ __ __ - __ __- __ __  

 
 
160  Specify other monoclonal antibody:    

 
 

161  Was mycophenolate mofetil (MMF, Cellcept) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

162  Was therapeutic mycophenolate mofetil (MMF, Cellcept) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
163    

gfedcb
Date therapeutic mycophenolate mofetil (MMF, Cellcept) stopped unknown

 
 

  
gfedcb

date estimated

 
 
Date therapeutic mycophenolate mofetil (MMF, Cellcept) stopped: __ __ __ __ - __ __- __ __  

 
 

164  Was tacrolimus (FK506, Prograf) given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

165  Was therapeutic tacrolimus (FK506, Prograf) stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
166    

gfedcb
Date therapeutic tacrolimus (FK506, Prograf) stopped unknown

 
 

  
gfedcb

date estimated

 
 
Date therapeutic tacrolimus (FK506, Prograf) stopped: __ __ __ __ - __ __- __ __  

 
 

167  Was any other immunosuppressive drug given as therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

168  Was therapeutic other immunosuppressive drugs stopped?

    
 nmlkji

yes  
 nmlkji

no  

 
 
169    

gfedcb
Date other therapeutic immunosuppressive drug stopped unknown

 
 

  
gfedcb

date estimated

 
 
Date therapeutic other other immunosuppressive drugs stopped: __ __ __ __ - __ __- __ __  

 
 
170  Specify other immunosuppressive drug:    

 
 

171  Was gene therapy performed (between diagnosis and prior to the preparative regimen)?

    
 nmlkji

yes  
 nmlkji

no  

 
 
172  Specify date of infusion of gene therapy: __ __ __ __ - __ __- __ __  

Form 2031 R3.0: Immune Deficiencies Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2031 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 11 / 12



 
 

173  Was the recipient considered to have failed gene therapy?

    
 nmlkji

yes  
 nmlkji

no  

 
 

174  Did the recipient receive any other significant treatment(s) (between diagnosis and prior to the preparative regimen)?

    
 nmlkji

yes  
 nmlkji

no  

 
 
175  Specify other treatment(s):    

 
 

176  Did the recipient receive parenteral nutrition (between diagnosis and prior to the preparative regimen)?

    
 nmlkji

yes  
 nmlkji

no  

 
 

177  Did the recipient receive mechanical ventilation (between diagnosis and prior to the preparative regimen)?

    
 nmlkji

yes  
 nmlkji

no  

 
 

178  Were any biologic specimens collected for this recipient (between diagnosis and prior to the preparative regimen)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify if specimen(s) collected and available for future research: 
 

179  DNA

    
 nmlkji

yes  
 nmlkji

no  

 
 

180  Epstein-Barr virus (EBV)-transformed B-Cell line

    
 nmlkji

yes  
 nmlkji

no  

 
 

181  Fibroblast cell line

    
 nmlkji

yes  
 nmlkji

no  

 
 

182  Herpes virus saimiri-transformed T-cell line

    
 nmlkji

yes  
 nmlkji

no  

 
 

183  Other T-cell line

    
 nmlkji

yes  
 nmlkji

no  

 
 

184  Pathological specimen

    
 nmlkji

yes  
 nmlkji

no  

 
 
185  Specify pathological specimen(s):    

 
 

186  Peripheral blood mononuclear cells (PBMC), frozen

    
 nmlkji

yes  
 nmlkji

no  

 
 

187  RNA

    
 nmlkji

yes  
 nmlkji

no  

 
 
188  Specify RNA source:    

 
 

189  Serum (pre-IVIG)

    
 nmlkji

yes  
 nmlkji

no  

 
 

190  Other specimen

    
 nmlkji

yes  
 nmlkji

no  

 
 
191  Specify other specimen(s):    

  
 
First Name:    

 
Last Name:    

  
 
Phone number:    

 
Fax number:    

 
 
E-mail address:    

Form 2031 R3.0: Immune Deficiencies Pre-HSCT Data  
Center:  CRID: 

             CIBMTR Form 2031 revision 3.0 last updated January 2010
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 12 / 12